All Releases
 |
Manhattan Pharmaceuticals, Inc. Reaches Agreement With the FDA on a Special Protocol Assessment for the Phase 3 Clinical Study of AST-726
Jul 21, 2011
|
7.6 KB |
|
| |
NEW YORK, July 21, 2011 (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAND) announced that the Company has reached an agreement with the U.S. Food and Drug Administration (FDA) on a special protocol assessment (SPA) for the design of a Phase 3 clinical trial of AST-726 in patients with a confirmed medical history of vitamin B12 defici...
|
|
Manhattan Pharmaceuticals, Inc. Announces Reverse Stock Split
Jul 13, 2011
|
9.5 KB |
|
| |
NEW YORK, July 13, 2011 (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) previously announced on Form 8-K that the Company's Certificate of Amendment to its Certificate of Incorporation (the "Amendment") to implement a 1-for-50 reverse stock split of its common stock, $0.001 par value per share (the "Common Stock") became effecti...
|
|
Manhattan Pharmaceuticals Achieves Ariston Merger Milestone
Jan 31, 2011
|
9.4 KB |
|
| |
NEW YORK, Jan. 31, 2011 (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) announced today that the company's Board of Directors has decided to continue development of AST-915, an orally delivered treatment for essential tremor. This decision was made following the announcement of favorable clinical results from a Phase 1/2 clinical s...
|
|
Manhattan Pharmaceuticals Announces Entry Into Settlement and Release Agreement With Nordic Biotech
Jan 10, 2011
|
9.6 KB |
|
| |
NEW YORK, Jan. 10, 2011 (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) announced that on January 4, 2011, the company entered into a settlement and release agreement with Nordic Biotech Fund II K/S and H Pharmaceuticals K/S. Manhattan Pharmaceuticals and Nordic are partners in the H Pharmaceuticals joint venture for the developmen...
|
|
Manhattan Pharmaceuticals Announces Preliminary Phase 1/2 Results for AST-915 in Essential Tremor
Dec 16, 2010
|
10.7 KB |
|
| |
NEW YORK, Dec. 16, 2010 (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) announced preliminary results today from a Phase 1/2 study of AST-915 for the treatment of essential tremor. Data from this single dose study demonstrated that AST-915 was safe and well tolerated and demonstrated a clear effect on tremor power.
In this ...
|
|
Manhattan Pharmaceuticals Awarded $245K Grant Under the U.S. Qualified Therapeutic Discovery Project Credit Program
Nov 8, 2010
|
7.0 KB |
|
| |
NEW YORK, Nov. 8, 2010 (GLOBE NEWSWIRE) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) announced today that it has been awarded $244,279 in funding under the U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) credit program. The Company has received this funding for its lead product candidate AST-726 for the treatment of vitamin B12...
|
|
Manhattan Pharmaceuticals to Present at Precision IR Biotech, Healthcare & Pharmaceutical Virtual Conference
Oct 11, 2010
|
6.8 KB |
|
| |
NEW YORK, Oct 11, 2010 (GlobeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) is scheduled to present at the Precision IR Biotech, Healthcare & Pharmaceutical Virtual Conference at 11:00 AM ET on Wednesday, Oct 13, 2010.
Dr. Malcolm Morville, Director of Manhattan Pharmaceuticals, will provide an overview of the...
|
|
Manhattan Pharmaceuticals Announces Private Placement Final Close at $3.0 Million
Apr 14, 2010
|
8.6 KB |
|
| |
NEW YORK, Apr 14, 2010 (GlobeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced the final close of its private placement in which it sold approximately 121 units, including the conversion of approximately $400,000 of existing debt into 17 units, for an aggregate of $3,029,386 of its common stock and wa...
|
|
Manhattan Pharmaceuticals Completes Merger Transaction With Ariston Pharmaceuticals
Mar 12, 2010
|
12.5 KB |
|
| |
NEW YORK, Mar 12, 2010 (GlobeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced it has entered into a definitive agreement and plan of merger and completed the merger transaction with Ariston Pharmaceuticals, Inc., a privately-held, specialty pharmaceutical company. As a result of the merger, Ariston b...
|
|
Manhattan Pharmaceuticals Completes $2.5 Million Financing
Mar 4, 2010
|
8.9 KB |
|
| |
NEW YORK, Mar 4, 2010 (GlobeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced the private placement of $2,547,500 of its common stock and warrants to accredited investors. The Company intends to complete the previously announced merger transaction with Ariston Pharmaceuticals, Inc. within the next two...
|
|
Manhattan Pharmaceuticals Provides Corporate Update on Hedrin and Management Restructuring
Jun 18, 2009
|
9.6 KB |
|
| |
NEW YORK, Jun 18, 2009 (GlobeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today provided an update on its ongoing development programs. The Company also announced it has initiated a management restructuring that is intended to extend the Company's resources and allow it to continue working toward its near-term c...
|
|
Manhattan Pharmaceuticals Completes $1 Million Financing
Nov 25, 2008
|
9.3 KB |
|
| |
NEW YORK, Nov 25, 2008 (GlobeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced that it has completed the first closing of a private placement of secured debt and warrants to purchase shares of its common stock. Pursuant to the terms of the private placement, the Company can sell up to 500 units to acc...
|
|
Manhattan Pharmaceuticals Announces Results of Phase 2a Study of Topical PTH (1-34) for the Treatment of Psoriasis
Jul 31, 2008
|
9.4 KB |
|
| |
NEW YORK, Jul 31, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced top-line results from its Phase 2a clinical study of topical PTH (1-34) for the treatment of psoriasis. This multi-center, randomized, double-blind, vehicle-controlled, parallel group study was designed to assess the safety...
|
|
Manhattan Pharmaceuticals Announces Amendment of Joint Venture Deal With Nordic Biotech
Jun 13, 2008
|
11.3 KB |
|
| |
NEW YORK, Jun 13, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced that the FDA has directed Hedrin(tm), a novel, non-insecticide treatment for pediculosis (head lice), to the Center for Devices and Radiological Health (CDRH) division of the U.S. Food and Drug Administration (FDA) for revi...
|
|
Manhattan Pharmaceuticals to Present At Rodman & Renshaw 5th Annual Global Healthcare Conference
May 19, 2008
|
8.2 KB |
|
| |
NEW YORK, May 19, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced that Douglas Abel, president and chief executive officer, will present at the Rodman & Renshaw 5th Annual Global Healthcare Conference on Tuesday, May 20 at 7:40 AM EDT (1:40 PM local time). The conference is being held May...
|
|
Manhattan Pharmaceuticals Announces Completion of Enrollment in Phase 2a Study of Topical PTH (1-34) for Psoriasis
Apr 10, 2008
|
10.5 KB |
|
| |
NEW YORK, Apr 10, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) announced today that it has completed patient enrollment in its ongoing Phase 2a clinical study of Topical PTH (1-34). This randomized, double-blind, vehicle-controlled, parallel group study is designed to evaluate safety and preliminary e...
|
|
Manhattan Pharmaceuticals to Trade on OTCBB Under New Ticker Symbol MHAN
Mar 26, 2008
|
7.5 KB |
|
| |
NEW YORK, Mar 26, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (OTCBB:MHAN) today announced that it has obtained a new ticker symbol, "MHAN". Effective immediately the company's common stock will begin trading under the new ticker symbol on the OTC Bulletin Board(r) (OTCBB), the over-the-counter equity securities ...
|
|
Manhattan Pharmaceuticals Successfully Completes Pre-IND Meetings for Altoderm and Altolyn
Mar 6, 2008
|
10.6 KB |
|
| |
NEW YORK, Mar 6, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that it has concluded successful pre-IND (Investigational New Drug) meetings with the U.S. Food and Drug Administration (FDA) and may file IND applications for both Altoderm(tm) and Altolyn(tm). The company intends to develop ...
|
|
Manhattan Pharmaceuticals Announces Closing of Joint Venture With Nordic Biotech
Feb 27, 2008
|
11.1 KB |
|
| |
NEW YORK, Feb 27, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced the closing of its joint venture agreement with Nordic Biotech Venture Fund II K/S (Nordic) to develop and commercialize Hedrin(tm), the company's novel, non-insecticide treatment for head lice for the North American market. ...
|
|
Manhattan Pharmaceuticals to Voluntarily Withdraw Its American Stock Exchange Common Stock Listing
Feb 22, 2008
|
10.7 KB |
|
| |
NEW YORK, Feb 22, 2008 (PrimeNewswire via COMTEX News Network) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that it has formally notified the American Stock Exchange ("AMEX") that it intends to voluntarily delist its common stock from AMEX. The company expects that the delisting will become effective within the next 25 calendar day...
|
|
|
